紫杉醇联合顺铂与替吉奥联合顺铂治疗中晚期非小细胞肺癌的疗效对比研究

Comparative study of curative effect of paclitaxel or S-1 combined with cisplatin in advanced non-small cell lung cancer

目的对比分析中晚期肺癌治疗中紫杉醇与替吉奥分别联合顺铂的治疗方案的疗效差异。方法 82例中晚期非小细胞肺癌中,以接受紫杉醇联合顺铂治疗的41例患者为对照组,接受替吉奥联合顺铂治疗的41例患者为观察组。对比两组近期疗效、远期疗效及不良反应发生率。结果经过4个疗程的治疗后,对照组治疗总有效率为19.51%,低于观察组的41.46%,差异有统计学意义(P﹤0.05)。随访结果显示,观察组中位生存期及中位无进展生存期分别为13.31个月及9.11个月,均高于对照组的10.83个月及8.28个月,差异有统计学意义(P﹤0.05)。此外,两组4个疗程治疗期间不良反应发生率比较,差异无统计学意义(P﹥0.05)。结论替吉奥联合顺铂治疗中晚期非小细胞肺癌相比紫杉醇联合顺铂治疗方案临床疗效及生存期更佳,且不良反应无明显增加。

Objective To compare the curative effect of paclitaxel and S-1 combined with cisplatin in the treatment of advanced non-small cell lung cancer （NSCLC）. Method 82 cases of advanced NSCLC were randomized into either control group （n=41） receiving paclitaxel＋cisplatin, or study group （n=41） with regimen of S-1＋cisplatin. The short-term, long-term efficacy as well as adverse reactions in both groups were compared. Result After four cycles of treat-ment, the overall response rate was 19.51%in control group, lower than that of study group at 41.46%, with significant difference observed （P〈0.05）. In the follow-up period, the median survival and median progression-free survival were 13.31 months and 9.11 months in study group, longer than that in control group at 10.83 months and 8.28 months, respec-tively （P〈0.05）. In addition, there was no statistical difference in respect of incidence of adverse reactions between the two groups （P〉0.05）. Conclusion The combined therapy of S-1 and cisplatin is better than paclitaxel plus cisplatin in the treatment of advanced non-small cell lung cancer, with superior clinical efficacy and longer survival, and less adverse reactions at the same time.